Chemistry & Industry Issue 1 - Cover Date Monday 7 January 2002January 02, 2002From Issue 1 2002 Chemistry & Industry has a new look and updated contents, including the launch of the C&I stock price indices. Based on the price of shares in 22 blue chip chemicals companies in Europe and North America, the value of the portfolio has been normalized to 100 and we await developments. Its value will be printed fortnightly on the regular Data page. Daily progress of the indices are also planned for the C&I website at www.chemind.org NEWS Cut price drugs anger pharma (page 4) Big pharma is threatening to withhold new drugs from European markets in a row over pricing policies. Diabetes testing with light (page 5) A device that measures blood glucose by shooting a beam of light at the forefinger could end the ritual bloodshed involved in diabetes testing. Urine test for Alzheimer`s (page 6) A urine test for Alzheimer`s is to be made available in the US from January 2002 BUSINESS Storm clouds gathering (page 8) It`s going to be a chilly winter and a late spring for parts of the chemical industry, says Simon Robinson, but it is too soon to rule out an Indian summer for the third quarter. DATA US pharma focus shifts from earnings to research (page 10) When US pharmaceutical giant Merck rocked the stock market on 12 December with the sobering announcement that its 2002 earnings would be flat, the company employed a catchphrase that might amply describe the outlook for the industry in general. FEATURES Oy Finland (page 15) Richard Butler reports from Finland, where clever investment in R&D and positive government involvement is fuelling a biotech explosion. Will the country outgrow its strength, or will foreign investors step in to support further development? Society of Chemical Industry |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||